| Literature DB >> 34969958 |
Nikolaus A Handke1,2, Dennis C Koch3, Eugen Muschler3, Daniel Thomas4, Julian A Luetkens4, Ulrike I Attenberger4, Daniel Kuetting4, Claus C Pieper4, Kai Wilhelm3.
Abstract
To evaluate the safety and impact of biopsy tract plugging with gelatin sponge slurry in percutaneous liver biopsy. 300 consecutive patients (158 females, 142 males; median age, 63 years) who underwent computed tomography-guided core biopsy of the liver in coaxial technique (16/18 Gauge) with and without biopsy tract plugging were retrospectively reviewed (January 2013 to May 2018). Complications were rated according to the common criteria for adverse events (NCI-CTCAE). The study cohort was dichotomized into a plugged (71%; n = 214) and an unplugged (29%; n = 86) biopsy tract group. Biopsy tract plugging with gelatin sponge slurry was technically successful in all cases. Major bleeding events were only observed in the unplugged group (0.7%; n = 2), whereas minor bleedings (4.3%) were observed in both groups (plugged, 3.6%, n = 11; unplugged, 0.7%, n = 2). Analysis of biopsies and adverse events showed a significant association between number of needle-passes and overall (P = 0.038; odds ratio: 1.395) as well as minor bleeding events (P = 0.020; odds ratio: 1.501). No complications associated with gelatin sponge slurry were observed. Biopsy tract plugging with gelatin sponge slurry is a technically easy and safe procedure that can prevent major bleeding events following liver biopsy.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34969958 PMCID: PMC8718535 DOI: 10.1038/s41598-021-04155-1
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Inclusion and exclusion criteria of the study cohort.
Figure 2CT-guided liver biopsy and post-interventional sonography. (a) Axial slice of the pre-interventional CT. Target lesion in segment 5/6. Arterial phase. (b,c) Correlating axial slices of the lesion in late portal and delayed phase. Adequate biopsy tract length. (d) Biopsy performed with a 16-G core needle coaxial system and an 18-G cutting needle. Intralesional location. (e) Post-interventional non-enhanced CT. Percutaneous tract embolization by gelatin sponge slurry. (f) Post-interventional ultrasound. Adequate distribution of hyperechoic gelatin foam slurry. No ascites. No haematoma.
Figure 3Preparation of gelatin sponge slurry. (a) Cutting gelatin foam in several small squares (5 x 5 mm). (b,c) Mixing 2 ml of compressed foam with 4 ml of 0.9% NaCl solution. (d) Viscous embolizate of gelatin sponge slurry.
Basic characteristics of the patients and Histology (separated in categories), given as median and range or N (%).
| Parameter | Valid, N | All patients | Plugged biopsy tract | Unplugged biopsy | P-value |
|---|---|---|---|---|---|
| No. of patients, N (%) | 300 | 300 (100) | 214 (71.3) | 86 (28.6) | |
| 0.126 | |||||
| Male | 142 (47.3) | 96 (44.9) | 46 (53.5) | ||
| Female | 158 (52.7) | 118 (55.1) | 40 (46.5) | ||
| Age (years) | 63.0 (25.0–88.0) | 63.0 (25.0–88.0) | 62.0 (27.0–87.0) | 0.310 | |
| PTT (s) | 297/212/85 | 28.0 (17.0–65.0) | 31.0 (17.0–65.0) | 26.0 (18.0–35.0) | < |
| INR | 295/212/85 | 1.0 (0.8–1.5) | 1.0 (0.8–1.5) | 1.0 (0.9–1.5) | 0.124 |
| Platelet count (G/l) | 298/212/86 | 247.5 (17.0–781.0) | 245.0 (17.0–781.0) | 252.0 (69.0–699.0) | 0.914 |
| Hgb (g/dl) | 298/212/86 | 12.4 (6.9–17.5) | 12.4 (7.2–17.5) | 12.5 (6.9–16.6) | 0.779 |
| Histology, N (%) | 300 | 214 | 86 | 0.754 | |
| Liver cancer | 46 (15.6) | 31 (14.5) | 15 (17.4) | ||
| Breast cancer | 40 (13.2) | 29 (13.6) | 11 (12.7) | ||
| Pancreatic cancer | 32 (10.6) | 21 (9.8) | 11 (12.7) | ||
| Colorectal Cancer | 15 (5.0) | 9 (4.2) | 6 (6.9) | ||
| Lung cancer | 13 (4.3) | 10 (4.7) | 3 (3.5) | ||
| Other malignancy | 81 (26.8) | 61 (28.5) | 20 (23.3) | ||
| Benign | 73 (24.5) | 53 (24.8) | 20 (23.3) | ||
Technical data, given as mean ± SD, median (range) or N (%).
| Parameter | Valid, N | All patients | Plugged biopsy tract | Unplugged biopsy tract | P-value |
|---|---|---|---|---|---|
| Diameter of the lesion (mm) | 278 | 37.0 (9.0–240.0) | 37.5 (9.0–240.0) | 37.0 (9.0–100.0) | 0.118 |
| 300 | 0.219 | ||||
| Right | 231 (77.0) | 169 (56.3) | 62 (20.1) | ||
| Left | 64 (21.3) | 43 (14.3) | 21 (7.0) | ||
| Bilobular | 5 (1.7) | 2 (0.7) | 3 (0.1) | ||
| Biopsy tract length (mm) | 300 | 40.0 (10.0–130.0) | 42.5 (10.0–120.0) | 34.0 (14.0–130.0) | |
| 300 | 0.544 | ||||
| Lateral | 125 (41.7) | 85 (28.3) | 40 (13.3) | ||
| Ventral | 171 (57.0) | 126 (42.0) | 45 (15.0) | ||
| Dorsal | 4 (1.3) | 3 (1.0) | 1 (0.3) | ||
| No. of biopsies | 300 | 4.0 (1.0–11.0) | 4.0 (1.0–10.0) | 3.0 (1.0–11.0) | < |
Postinterventional adverse events and corresponding CTCAE category, given as N (%).
| Parameter | Valid, N | All patients | Plugged biopsy tract | Unplugged biopsy tract | P-value |
|---|---|---|---|---|---|
| Complications, overall N (%) | 300 | 19 (6.3) | 12 (5.6) | 7 (8.1) | |
| 15 (5.0) | 11 (5.1) | 4 (4.6) | 0.829 | ||
| Minor bleeding (CTCAE 1), N (%) | 13 (4.3) | 11 (5.1) | 2 (2.3) | 0.265 | |
| Major bleeding (CTCAE 3 + 4), N (%) | 2 (0.7) | 0 (0.0) | 2 (2.3) | ||
| Colon perforation (CTCAE 2), N (%) | 1 (0.3) | 0 (0.0) | 1 (1.2) | 0.118 | |
| Pneumothorax (CTCAE 3), N (%) | 3 (1.0) | 1 (0.5) | 2 (2.3) | 0.151 |
Logistic regression analysis of the cohort given as N (%), Odds ratio (OR) with 95% confidence intervals (CI).
| Parameter | N | OR | 95% CI | P-value |
|---|---|---|---|---|
| 15 | ||||
| Curaspon | 0.762 | 0.218–2.670 | 0.671 | |
| Sex | 0.876 | 0.297–2.588 | 0.811 | |
| Diameter | 1.009 | 0.994–1.024 | 0.247 | |
| Biopsy tract | 0.985 | 0.955–1.016 | 0.341 | |
| No. of biopsies | 1.395 | 1.018–1.913 | ||
| PTT | 0.977 | 0.892–1.069 | 0.610 | |
| INR | 0.989 | 0.978–1.001 | 0.972 | |
| Platelet count | 0.999 | 0.994–1.004 | 0.815 | |
| Hgb | 0.798 | 0.614–1.036 | 0.090 | |
| 2 | ||||
| Curaspon | 0.000 | 0.000 | 0.995 | |
| Sex | 0.000 | 0.000 | 0.995 | |
| Diameter | 0.987 | 0.898–1.086 | 0.794 | |
| Biopsy tract | 0.946 | 0.826–1.084 | 0.424 | |
| No. of biopsies | 0.927 | 0.338–2.544 | 0.883 | |
| PTT | 0.000 | 0.000 | 0.961 | |
| INR | 0.990 | 0.979–1.001 | 0.897 | |
| Platelet count | 1.618 | 0.000 | 0.951 | |
| Hgb | 77.936 | 0.000 | 0.980 | |
| 13 | ||||
| Curaspon | 1.439 | 0.291–7.106 | 0.655 | |
| Sex | 1.224 | 0.377–3.979 | 0.736 | |
| Diameter | 1.010 | 0.995–1.026 | 0.181 | |
| Biopsy tract | 0.988 | 0.956–1.021 | 0.465 | |
| No. of biopsies | 1.501 | 1.066–2.113 | ||
| PTT | 0.998 | 0.912–1.092 | 0.967 | |
| INR | 0.990 | 0.978–1.001 | 0.929 | |
| Platelet count | 0.997 | 0.991–1.003 | 0.286 | |
| Hgb | 0.804 | 0.606–1.067 | 0.131 |